Theravance BioPharma senior vice president of development and operations Frank Pasqualone says the Vibativ (telavancin) relaunch "has gone just about as well as expected" and it has been helped by the company's growing collection of data for the intravenous antibiotic.
Theravance BioPharma senior vice president of development and operations Frank Pasqualone says the Vibativ (telavancin) relaunch "has gone just about as well as expected" and it has been helped by the company's growing collection of data for the intravenous antibiotic.
South San Francisco-based Theravance Biopharma presented data from multiple in vitro studies that showed Vibativ was superior to competing drugs...
Create an account to read this article
Already a subscriber?
The drugmaker announced the launch of an at-home version of its nasal FluMist vaccine, as more companies are looking into direct-to-patient drug sales in response to Trump’s most favored nation pricing proposals.
The news will have a big impact on pandemic preparedness but less immediate financial impact. Tiba Biotech was even “caught off guard” by its inclusion in the department’s culling of mRNA vaccine projects under BARDA, as its project was neither a vaccine nor mRNA-based.
Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.
Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.
The microbiome-based company’s trial of VE202 in ulcerative colitis has failed in Phase II, but its ongoing Phase III study in C difficile infection is more promising.
The company will move ahead in testing RDX-002 among overweight and obese patients coming off GLP-1s, but the CEO said antipsychotic-induced weight gain could represent a multibillion-dollar market.
Deupirfenidone hit its Phase II endpoint but the program remains risky and PureTech’s new Celea Therapeutics will aim to pull in extra funding for its late-stage development.
